Shengshitai Biopharmaceutical Technology

About Shengshitai Biopharmaceutical Technology

Shengshitai Biopharmaceutical Technology (CGeneTech), established in 2010 within Suzhou Industrial Park, is a commercial-stage biopharmaceutical firm concentrated on the development and commercialization of small-molecule drugs. The company was founded by Dr. Qiang Yu, who serves as CEO, and Juping Ding, who is the Chairman and President. Dr. Yu's background includes a Ph.D. in chemistry from The University of Kansas, postdoctoral work at its School of Pharmacy, and roles at US-based pharmaceutical technology companies where he led collaborations with major firms like Eli Lilly and GlaxoSmithKline. Juping Ding holds a master's in medicinal chemistry from the Chinese Academy of Medical Sciences and has nearly three decades of experience in the pharmaceutical industry, specializing in the full-chain management of new drug R&D and industrialization.

The company's business model is centered on internal research, development, and eventual commercialization of a differentiated pipeline of pharmaceutical products. CGeneTech operates in the biopharmaceutical market, addressing high-demand therapeutic areas including metabolic diseases (specifically diabetes), oncology, and autoimmune disorders. Revenue is generated through the sale of its approved drugs. The core of its operation is an integrated drug R&D platform that enables the discovery and development of its candidates.

A key milestone for the company was the market approval of its Class 1 innovative drug, Sentagliptin (Shenggliptin), a highly selective DPP-4 inhibitor for treating type 2 diabetes. This drug was part of China's 12th and 13th Five-Year Major New Drug Creation Programs and received approval after demonstrating superior efficacy in Phase I trials and strong safety and performance in Phase III trials. Beyond Sentagliptin, CGeneTech's pipeline includes several other promising assets. In the oncology space, four candidates have entered clinical trials, including a dual FGFR/VEGFR inhibitor for advanced solid tumors and a CDK4/6 inhibitor for acute myeloid leukemia (AML). The company is also developing a small molecule oral CXCR4 antagonist for hematopoietic stem cell mobilization and a next-generation ALK inhibitor to address drug resistance and brain metastasis in lung cancer, both of which have received clinical trial approval from the US FDA.